Foghorn Therapeutics Stock Today
| FHTX Stock | USD 4.12 0.32 7.21% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Foghorn Therapeutics is trading at 4.12 as of the 21st of March 2025; that is 7.21 percent decrease since the beginning of the trading day. The stock's open price was 4.44. Foghorn Therapeutics has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of October 2020 | Category Healthcare | Classification Health Care |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. The company has 55.61 M outstanding shares of which 965.32 K shares are currently shorted by private and institutional investors with about 6.16 trading days to cover. More on Foghorn Therapeutics
Moving against Foghorn Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Foghorn Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Adrian Gottschalk | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsFoghorn Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Foghorn Therapeutics' financial leverage. It provides some insight into what part of Foghorn Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foghorn Therapeutics (FHTX) is traded on NASDAQ Exchange in USA. It is located in 500 Technology Square, Cambridge, MA, United States, 02139 and employs 112 people. Foghorn Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 246.92 M. Foghorn Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 55.61 M outstanding shares of which 965.32 K shares are currently shorted by private and institutional investors with about 6.16 trading days to cover.
Foghorn Therapeutics currently holds about 373.5 M in cash with (100.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Foghorn Therapeutics Probability Of Bankruptcy
Ownership AllocationFoghorn Therapeutics holds a total of 55.61 Million outstanding shares. The majority of Foghorn Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Foghorn Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Foghorn Therapeutics. Please pay attention to any change in the institutional holdings of Foghorn Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Foghorn Ownership Details
Foghorn Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-12-31 | 567.4 K | |
| Alphabet Inc | 2024-12-31 | 500.9 K | |
| Birchview Capital, Lp | 2024-12-31 | 310.9 K | |
| Northern Trust Corp | 2024-12-31 | 253.7 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 223.8 K | |
| Dafna Capital Management Llc | 2024-12-31 | 186.7 K | |
| Sio Capital Management, Llc | 2024-12-31 | 121.7 K | |
| D. E. Shaw & Co Lp | 2024-12-31 | 100.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 97.5 K | |
| Flagship Ventures Management, Inc. | 2024-12-31 | 12.7 M | |
| Fmr Inc | 2024-12-31 | 5.7 M |
Foghorn Therapeutics Historical Income Statement
Foghorn Stock Against Markets
Foghorn Therapeutics Corporate Management
| Karin Hellsvik | Corporate VP | Profile | |
| Saurabh Sewak | Vice Development | Profile | |
| Kristian MBA | Chief Officer | Profile | |
| Allan MD | Chief Officer | Profile | |
| Alfonso MD | Chief Officer | Profile |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.